4.5 and 5.2). The c oncomi tant use of  ZE PATIER  and strong CYP3A  inhibitors increases elbasvir and grazoprevirconcentrations
, and co -administration  is not recommended
 (see section  4.5). HCV/HBV (hepatitis B virus) c o-inf ection 
 Cases of hepatitis B  virus (HBV) reactivation,
 some of them f atal, have been reported during or af tertreatment with
 direct-acting antiviral agents. HBV screening should be perf ormed in all patients beforeinitiation of  treatment. HBV/HCV
 co-infected patients are at risk of  H BV reactivation, and shouldtheref ore be monit ored a nd manage d according to current clinical guidelines.Use in diabetic patients 
 Diabetics may experience improved glucose control potentially resulting in symptomatichypog lycaemia , after initiating  HCV direct acting antiviral (DAA) treatment. Gl ucose  level s ofdiabetic patients initiating DAA therap y should be closely monitored, particularly within the f irst
3 months, and their diabetic medication modif ied when necessary. T he physician in charge of  thediabetic care of  the patient should  be inf or med w hen DAA therapy is init iated.Paediatric population 
 ZEPATIER  is not indicated f or use in children under 12 years of  age .Excipien ts 
 ZEPATIER contain s lactose  monoh ydrate. Patients with rare hereditary problems of  galactoseintoleran ce, total lactase def iciency
, or glucose
-galactose malabsorption should not take this medicinalproduct .ZEPATIER contains 
69.85 mg sodium per tablet, equivalent to 3.5 % of  the WHO recomme ndedmaximum daily intake of  2
 g sodium  f or a n adult.
4.5 Interac tion with other medicinal products and other forms o f interaction 
 Potential f or other  medicinal  products to af f ect ZEPATIERGrazoprevir is  a substrate of OATP1 B drug tran sporters. Co -administration of  ZEPATIER withmedicinal products that inhibit OATP1B transporters is contraindicated because it
 may resul t in asignificant increase in the  plasma concentration of  grazoprevir ( see sections 4.3 and 4.4).Elbasvir and grazopr evir are substr ates of  CYP3A  and P-gp. Co -admi nistration of inducers of  CYP
3Aor P-gp with ZEPATIER  is contraindicated because
 it may de creas e elbasvir and grazoprev ir plasmaconcentrations, which may lead to  reduce d therape utic ef f ect of ZEPATI ER (see sec tions 4.3 and 4 .4). Co-administration of  ZEPATIER  with strong CYP3A inhibitors inc reases elbasvir and grazop revirplasma con centration s, and co-administration is
 not recommended  (see Table  2 and sect ion 4.4).6Co-administra tion of  ZEP ATIER with P-gp inhib itors is expected to have a minimal eff ect on theplasma concentrations of ZEPATIER.The potential f or grazoprevir to be a breast cance r resistance protein ( BCRP ) substr ate cannot  beexcluded.Potent ial f or  ZEPATI ER to af f ect other m edicinal products 
 Elbasvir and grazoprevir are inh ibitors of the drug transpo rter BCRP  at the i ntestinal  level in humansand may increase plasma concentrati ons o f co-administered BCRP substr ates. Elbasvir is not a 
 CYP3A i nhibito r in vitro and g razop revir is a weak CYP3 A inhib itor in humans.
 Co-administrat ionwith grazoprevir did not result in clinically rele vant increases in exposures of  CYP3A substrates.Theref or e, no dose adjustment is
 required f or CYP3A substrates when co-admi nistered with 
 ZEPATIE R. Elbasvir has minimal i ntestinal P -gp inhibition in humans, and does not result in clinically relevantincreases in concentrations of
 digoxin (a P
-gp substrate ), with an 11% increase in plasma AUC.Grazoprevir is not a P
-gp inhibit or based on in vitro data. Elbasvir and grazopre vir are not OATP1Binhibitors in humans. Based
 on in vitro data, clinically
 signif ic ant interactions with ZEPATIER as aninhib itor of  ot her C YP enzymes, UGT1A1, esterases  (CES1, CES2, and Cat 
 A), OAT1, OAT3, a nd 
 OCT2  are not expec ted. Based on in vitro data, a potential f or GZR to inhibit BSEP cannot beexcluded.  Multiple -dose adm inistrati on of elbasvir or grazoprevir is unlikely to induce the m etabolismof  medicinal produc ts metabol ised by CYP isof orms based o n in vitro data. Patients  treated w ith vitamin  K antagonists As liver f unction may change during treatment with ZEPATIE R, a clos e mo nitoring of International 
 Normalised Ratio (INR)  values is recommended.Impa ct of DAA therapy on drugs metabolized by the liver 
 Grazop revir’s wea k inhibition of  CYP3A  may increase levels of CYP3A substrates. In addition, theplasma concentrations  of drugs that are CYP3A substrates  may be decreased  by improvement in liverf unction  during DAA  therapy, related to clearance o f HCV. Theref ore , close mon itoring and potentialdose adjustment of CYP3A substrates with a narrow therapeutic index (e.g.,
 calci neurin inhibitors)may be required during therapy, as d rug levels may change  (see Ta ble 2).Interactions between ZEPATI ER and other medicinal products Table 2 provides a li sting of assessed or potential  medicinal product interactions. An up “↑” or  down
“↓” arrow represents a change in exposure that requires monitoring or a dose adjustment of  thatmedication, or the co
-administration is not recommended or
 contraind icated. No clinically relevantchange  in exposure is represented by a horizontal arrow
 “↔”. The medicinal product interactions described are based on results f rom studies conducted with either 
 ZEPATIER or elbasvir (EBR) and grazoprevir (GZR) as
 individua l agents, o r are predicted
 medicinalproduct interactions that may occur with elbasvir
 or grazoprevir. The table is not all
-inclusive.7Table 2: Interactions and dose recommendations with other medicinal products 
 Medicin al product by therapeutic areas  Effects on medi cinal product levels.  Mean ratio (90
 
% confidence
 interv al) for AUC, Cmax, C12 or C24(likely mechanism of interaction)Recom mendation concerning co
-administration with ZEPATIERACID REDUCING AGENTS H2-receptor antagonists 
 Famotid ine  (20 m g single dose)/ elbasvir ( 50 mg single dose)/ grazoprevir (10 0 mg si ngle dose)  ↔ Elba svir AUC 
1.05 (0.92, 1.18) Cmax 
1.11 (0.98, 1.26) C24 1.03 (0.91, 1.17)
↔ Grazoprevir 
 AUC 1.10 (0.95, 1.28) Cmax  0.89 (0.71, 1.1 1) C24 1.12 (0.97, 1.30)No dose adj ustm ent is required .Proton pump inhibitors 
 Pantoprazole  (40 mg once daily)/ elbasvir (50 mg single dose) / grazoprevir (100 mg single do se)  ↔ E lbasvir  AUC 1.05 (0.93, 1.18) 
 Cmax 
1.02 (0.92, 1.14) C24
1.03 (0.92, 1. 17)
↔ Grazoprevir 
 AUC 1.12  (0.96, 1. 30) Cmax 1.10 (0.89, 1.37 ) C24 1.17 (1.02, 1.34)No dose  adjustmen t is require d.Antacids 
 Aluminium or magnesium hydroxide; calcium carbonate   Interaction not studied. 
 Expected:  
↔ Elbasvir
↔ Grazoprevir 
 No dose a djustment  is required .ANTIARRHYTHM ICSDigoxi n (0.25  mg sing le dose)/  elbasvir (50 mg once  daily) ↔ D igoxin AUC 1 .11 (1.02, 1.22 )Cmax 
1.47 (1.25, 1.73) (P-gp inhibition )No dose adjustment is required.ANTICOAGULANTSDabigatran  etexilate  
 Interact ion not studied. Expected:  
↑ Dabiga tran(P-gp inhibition)Concentrations of  dabigatran mayincrease wh en co -admini stered withelbasvir
, with possible increased bleedingrisk. Clini cal and laboratory  monito ring isrecommended. Vitamin Kantagonists 
 Interaction not studied. Close monito ring of  INR  is recommendedwith all vitamin K antagonists
. This is dueto liver f unction changes during treatmentwith ZEPATIER.ANTICONVULSANTSCarbamazepine  Phenytoin  Interaction not studied. Expected: 
↓ Elbasvir
↓ Grazoprevir(CYP3A or P -gp induction)Co-administration is contraindicated.8Medicin alproduct bytherapeuticareas Effects on medi cinal product levels. Mean ratio (90
 
% confidence
 interv al)for AUC, Cmax, C12 or C24(likely mechanism of interaction)Recom mendation concerning co
-administration with ZEPATIERANTIFUNGALSKetoconazole(400 mg PO oncedaily)/ elbasvir(50 mg single dose)
↔ Elbasvir 
 AUC 1.80 (1.41, 2.29)Cmax 
1.29 (1.00, 1.66) C24 1.89 (1.37, 2.60)Co-administration is not recommended.(400 mg PO oncedaily)/ grazoprevir(100 mg singledose)↑ Grazoprevir 
 AUC 3.02 (2.42, 3.76) Cmax 1.13 (0.77, 1.67)(CYP3A inhibition)ANTIMYCOBACTERIALSRif ampicin(600 mg IV single dose)/ elbasvir (50 mg single d ose) 
 ↔ Elb asvir 
 AUC 1.22 (1.06, 1.40)Cmax 
1.41 (1.18, 1.68) C24 
1.31 (1.12, 1.53) Co-administration is contraindicated.(600 mg IV single dose)/ grazoprevir (200 mg single dose)  
 
 ↑ Grazoprevir 
 AUC 10.21 (8.68, 12.00) Cmax 
10.94 (8.92, 13.43)C24 1.77 (1.40, 2 .24) (OATP1B inhibition)(600 mg PO single dose)/ elbasvir (50 mg single dose)
 
 ↔ Elbasvir 
 AUC 1.17 (0.98, 1.39)Cmax 
1.29 (1.06, 1.58) C24 1.21 (1.03, 1.43)(600 mg PO single dose)/ grazoprevir (200 mg once daily)  
 ↑ Grazoprevir 
 AUC 8.35  (7.38, 9.4 5)Cmax 
6.52 (5.16, 8.24) C24 1.31 (1.12, 1.53)(OATP1B inhibition)(600 mg PO oncedaily)/ grazoprevir(200 mg oncedaily) ↔ Grazoprevir 
 AUC 0.93 (0.75, 1.17) Cmax 
1.16 (0.82, 1.65) C24 0.10 (0.07, 0.13)(OATP1B inhibition and CYP3A induction)ASTHMA AGENTSMontelukast  (10 mg single dose)/ grazoprevir (200 mg single dose)↔ Montelukast 
 AUC 1.11 (1.01, 1.20)Cmax 
0.92 (0.81, 1.06) C24 1.39 (1.25, 1.56)No dose adjustment is required
.ENDOTHELIN ANTAGONISTBosentan  Interaction not studied. Expected: 
↓ Elbasvir
↓ Grazop revir(CYP3A or P -gp induction)Co-administration is contraindicated.9Medicin al product by therapeutic areas  Effects on medi cinal product levels. Mean ratio (90
 
% confidence
 interv al)for AUC, Cmax, C12 or C24(likely mechanism of interaction)Recom mendation concerning co
-administration with ZEPATIERHCV ANTIVIRAL AGENTSSof osbuvir  (400 mg single dose sof osbuvir)/ elbasvir (50 mg once daily)/grazoprevir(200 mg once daily↔ Sofosbuvir 
 AUC 2.4 3 (2.12, 2. 79)Cmax 
2.27 (1.72, 2.99) 
↔ GS -331007AUC 1.13 (1.05, 1.21)Cmax 
0.87 (0.78, 0.96) C24 1.53 (1.43, 1.63)No dose adjustment is required. HERBAL SUPPLEMENTSSt. John’s wort (Hypericum perforatum ) Interaction not studied. Expected: 
↓ Elba svir
↓ Graz oprevi r(CYP3A or P -gp ind uction)Co-administration is contraindicated.HBV AND HIV ANTIVIRAL AGENTS: NUCLEOS(T)IDE REVERSE TRANSCRIPTASEINHIBITORSTenof ovir disoproxil f umarate(300 mg once daily)/ elbasvir (50 mg once daily)  ↔ Elbasvir 
 AUC 0.93 (0.8 2, 1.05)Cmax 0.88 (0.77, 1 .00) C24 
0.92 (0.18, 1.05) 
↔ Tenofovir AUC 1.34 (1.23, 1.47)Cmax 
1.47 (1.32, 1.63) C24 
1.29 (1.18, 1.41) No dose adjustment is required
. (300 mg oncedaily)/ grazoprevir(200 mg oncedaily)↔ Grazoprevir 
 AUC  0.86 (0.55 , 1.12)Cmax 0.78 (0.51, 1. 18) C24 
0.89 (0.78, 1.01) 
↔ Tenofovir AUC 1.18 (1.09, 1.28)Cmax 
1.14 (1.04, 1.25) C24 1.24 (1.10, 1.39)(300 mg oncedaily)/elbasvir(50 mg oncedaily)/grazoprevir(100 mg oncedaily)↔ Tenofovir AUC 1.27 (1.2 0, 1.35)Cmax 
1.14 (0.95, 1.36) C24 1.23 (1.09, 1.40)10Medicin alproduct bytherapeuticareas Effects on medi cinal product levels. Mean ratio (90
 
% confidence
 interv al)for AUC, Cmax, C12 or C24(likely mechanism of interaction)Recom mendation concerning co
-administration with ZEPATIERLamivudine 
 Abacavir 
 Entecavir 
 Interaction not studied. Expected: 
↔ Elbasvir
↔ Grazoprevir
↔ Lamivudine
↔ Abacavir
↔ Entecavir 
 No dose adjustment is required
. Emtricitabine(200 mg oncedaily)Interaction st udied withelvitegravir/cob icistat/emtricitabine/tenof ovirdisoproxil f umarate (f ixed
-dosecombination)
↔ Emtricitabine 
 AUC 1.07 (1.03, 1.10)Cmax 
0.96 (0.90, 1.02) C24 1.19 (1.13, 1.25)No dose adjustment is required
.HIV ANTIVIRAL AGENTS: PROTEASE INHIBITORSAtazanavir/ritonavir(300 mg once daily)/ ritonavir (100 mg once daily/ elbasvir (50  mg once daily)  
 ↑ Elbasvir  AUC 4.76 (4.07, 5.56)Cmax 
4.15 (3.46, 4.97) C24 6.45 (5.51, 7.54)(combination of  mechanisms including 
 CYP3A inhibition
)
↔ Atazan avir 
 AUC 1.07 (0.98, 1.17) Cmax 
1.02 (0.96, 1.08) C24 1.15 (1.02, 1.29)Co-administration is contraindicated.(300 mg oncedaily)/ ritonavir(100 mg once daily/grazoprevir(200 mg oncedaily)↑ Grazoprevir  AUC 10.58 (7.78, 14.39) Cmax 6.24 (4.42, 8. 81) C24 
11.64 (7.96, 17.02
)(combination of  OATP1B and CYP3Ainhibition)
↔ Atazanavir 
 AUC 1.43 (1.30, 1.57) Cmax 
1.12 (1.01, 1.24) C24 1.23 (1.13, 2.34)  11Medicin alproduct bytherapeuticareas Effects on medi cinal product levels. Mean ratio (90
 
% confidence
 interv al)for AUC, Cmax, C12 or C24(likely mechanism of interaction)Recom mendation concerning co
-administration with ZEPATIERDarunavir/ritonavir(600 mg twicedaily)/ ritonavir(100 mg twicedaily/ elbasvir(50 mg once daily)↔ Elbasvir 
 AUC 1.66  (1.35, 2.05)Cmax 
1.67 (1.36, 2.05) C24 1.82 (1.39, 2.39)
↔ Darunavir 
 AUC 0.95 (0.86, 1.06)
 Cmax 
0.95 (0.85, 1.05) C12 0.94 (0.85, 1.05)Co-administration is contraindicated.(600 mg twicedaily)/ ritonavir(100 mg twicedaily/ grazoprevir(200 mg on cedaily)↑ Grazoprevir  AUC 7.50 (5.92, 9.51)Cmax 5.27 (4.04, 6.86)C24 
8.05 (6.33, 10.24)
  (combination of  OATP1B and CYP3Ainhibition)
↔ Darunavir 
 AUC 1.11 (0.99, 1.24)Cmax 
1.10 (0.96, 1.25) C12 1.00 (0.85, 1 .18)Lopin avir/ritonavir(400 mg twi cedaily)/ ritonavir(100 mg twicedaily/ elbasvir(50 mg once daily)↑ Elbasvir 
 AUC 3.71 (3.05, 4.53)Cmax 
2.87 (2.29, 3.58) C24 4.58 (3.72, 5.64)(combination of  mechanisms including 
 CYP3A inhibition)
↔ Lopinavi r 
 AUC 1.02 ( 0.93, 1.13)Cmax 1.02 (0.92 , 1.13) C12 1.07 (0.97, 1.18)Co-administration is contraindicated.(400 mg twicedaily)/ ritonavir(100 mg twicedaily/ grazoprevir(200 mg oncedaily)↑ Grazoprevir  AUC 12.86 (10.25, 16.13)Cmax 7.31 (5.65, 9.45)  C24 21.70 (12.99, 36.25)(combinatio n of  OATP1B and CYP3Ainhibition)
↔ Lopinavir 
 AUC 1.03 (0.96, 1.16)Cmax 0.97 (0.88, 1.08)C12 
0.97 (0.81, 1.15) 
 Saquinavir/ritonavir 
 Tipranavir/ritonavir 
 Atazanavir 
 Interaction not studied.Expected: 
↑ Grazopre vir(combination of  mechanisms including 
 CYP3A inhibition)Co-administration is contraindicated.12Medicin al product by therapeutic areas  Effects on medi cinal product levels.  Mean ratio (90
 
% confidence
 interv al) for AUC, Cmax, C12 or C24(likely mechanism of interaction)Recom mendation concerning co
-administration with ZEPATIERHIV ANTIVIRAL AGENTS: NON
-NUCLEOSIDE HIV REVERSE TRANSCRIPTASEINHIBITORSEf avirenz(600 mg once daily)/ elbasvir (50 mg once daily)  ↓ Elbasvir  AUC 0.46 (0 .36, 0.59)Cmax 
0.55 (0.41, 0.73) C24 0.41 (0.28, 0.59)(CYP3A or P -gp induction)
↔ Efavirenz 
 AUC 0.82 (0.78, 0.86)Cmax 
0.74 (0.67, 0.82) C24 0.91 (0.87, 0.96)Co-administration is contraindicated.(600 mg oncedaily)/ grazoprevir(200 mg oncedaily)↓Grazoprev ir 
 AUC 0.17 (0.13, 0.24)Cmax 0.13 (0.09, 0.19)C24 0.31 (0.25, 0.38)(CYP3A or P -gp induction)
↔ Efavirenz 
 AUC 1.00 (0.96, 1.05)Cmax 
1.03 (0.99, 1.08) C24 0.93 (0.88, 0.98)Etravirine 
 Interaction not studied. Expected: 
↓ Elbasvir
↓ Gra zoprevir(CYP3A or P -gp induction)Co-administration is contraindicated.Rilpivirine(25 mg once daily)/elbasvir (50  mgonce daily)/grazoprevir(200 mg oncedaily) ↔ Elbasvir 
 AUC 1.07 (1.00, 1.15)Cmax 
1.07 (0.99, 1.16) C24 
1.04 (0.98, 1.11) 
↔ Gra zoprevir 
 AUC  0.98 (0.89, 1.07)Cmax 0.97 (0.83, 1.14) C24 
1.00 (0.93, 1.07) 
↔ Rilpivirine 
 AUC 1.13 (1.07, 1.20)Cmax 
1.07 (0.97, 1.17) C24 
1.16 (1.09, 1.23) No dose adjustment
 is required.13Medicin al product by therapeutic areas  Effects on medi cinal product levels.  Mean ratio (90
 
% confidence
 interv al) for AUC, Cmax, C12 or C24(likely mechanism of interaction)Recom mendation concerning co
-administration with ZEPATIERHIV ANTIVIRAL AGENTS: INTEGRASE STRAND TRANSFER INHIBITORSDolutegravir  (50 mg single dose)/ elbasv ir (50 mg once daily)/ grazoprevir (200 mg once daily)  
 ↔ Elbasvir  AUC 0.98 (0.93, 1.04)Cmax 
0.97 (0.89, 1.05) C24 
0.98 (0.93, 1.03) 
↔ Grazoprevir 
 AUC 0.81 (0.67, 0.97)Cmax 
0.64 (0.44, 0.93) C24 0.86 (0.79, 0.9 3) 
↔ Dolut egravir 
 AUC 1.16 (1.00, 1.3
4)Cmax 
1.22 (1.05, 1.40) C24 
1.14 (0.95, 1.36) No dose adjustment is required
.Raltegravir(400 mg singledose)/ elbasvir(50 mg single dose)
↔ Elbasvir 
 AUC 0.81 (0.57, 1.17)Cmax 
0.89 (0.61, 1.29) C24 0.80 (0. 55, 1.16) 
↔ Raltegravir 
 AUC 1.02 (0.8 1, 1.27)Cmax 
1.09 (0.83, 1.44) C12 
0.99 (0.80, 1.22) No dose adjustment is required
.(400 mg twicedaily)/ grazoprevir(200 mg oncedaily) ↔ Grazoprevir 
 AUC 0.89 (0.72, 1.09)Cmax 
0.85 (0.62, 1.16) C24 0.90 (0. 82, 0.99) 
↔ Raltegravir 
 AUC 1.43 (0.8 9, 2.30)Cmax 
1.46 (0.78, 2.73) C12 1.47 (1.08, 2.00)14Medicin al product by therapeutic areas  Effects on medi cinal product levels.  Mean ratio (90
 
% confidence
 interv al) for AUC, Cmax, C12 or C24(likely mechanism of interaction)Recom mendation concerning co
-administration with ZEPATIERHIV ANTIVIRAL AGENTS: OTHERElvitegravir/cobicistat/emtricitabine/tenof ovir disoproxil f umarate (f ixed
-dose combination)elvitegravir (150 mg once daily)/cobi cistat (150 mg once daily)/ emtricitabi ne (200 mg once daily)/ tenof ovir disoproxil f umarate (300 mg once daily)/elbasvir (50 mg once daily)/ grazoprevir (100 mg once daily)  
 ↑ Elbasvir  AUC 2.18 (2.02, 2.35)
 Cmax 
1.91 (1.77, 2.05) 
 C24 2.38 (2.19, 2.60)  
 (CYP3A and OATP1B inhibition)
 
 
↑ Grazoprevir 
 AUC 5.36 (4.48, 6.43)Cmax 
4.59 (3.70, 5.69) C24 
2.78 (2.48, 3.11) (CYP3A and OATP1B inhibition)
↔ Elvitegravir 
 AUC 1.10 (1.00,  1.21)Cmax 
1.02 (0.93, 1.11) C24 
1.31 (1.11, 1.55) 
↔ Cobicistat 
 AUC 1.49 (1. 42, 1.57)Cmax 
1.39 (1.29, 1.50) 
↔ Emtricitabine 
 AUC 1.07 (1.03, 1.10)Cmax 
0.96 (0.90, 1.02) C24 
1.19 (1.13, 1.25) 
↔ Tenofovir AUC 1.18 (1.13, 1.24)Cmax 1.25 (1.14, 1.3 7) C24 1.20 (1.15, 1.26)Co-administration with ZEPATIER iscontraindicated.HMG -Co 
 A REDUCTASE INHIBITORSAtorvastatin(20 mg single dose)/ grazoprevir (200 mg once daily)  
 ↑ Atorvastatin 
 AUC 3.00 (2.42, 3.72)Cmax 
5.66 (3.39, 9.45) (primarily due to intestinal BCRP inhibition)
↔ Grazoprevir 
 AUC 1.26 (0.97, 1.64)Cmax 1.26 (0.83, 1.9 0) C24 
1.11 (1.00, 1.23) The dose of  atorvastatin should notexceed a daily dose of  20
 mg whenco-administered with ZEPATIER.(10 mg singledose)/ elbasvir(50 mg once daily)
/ grazoprevir(200 mg oncedaily) ↑ Atorvastatin 
 AUC 1.94 (1.63,  2.33)Cmax 
4.34 (3.10, 6.07) C24 
0.21 (0.17, 0.26) 15Medicin alproduct bytherapeuticareas Effects on medi cinal product levels. Mean ratio (90
 
% confidence
 interv al)for AUC, Cmax, C12 or C24(likely mechanism of interaction)Recom mendation concerning co
-administration with ZEPATIERRosuvastatin(10 mg singledose)/ grazoprevir(200 mg oncedaily) ↑ Rosuvastatin 
 AUC 1.59 (1.33, 1.89)
 Cmax 4.25 (3. 25, 5.56) C24 
0.80 (0.70, 0.91) (intestinal BCRP inhibition)
↔ Grazoprevir 
 AUC 1.16 (0.9 4, 1.44)Cmax 
1.13 (0.77, 1.65) C24 
0.93 (0.84, 1.03) The dose of  rosuvastatin should notexceed a daily dose of  10
 mg whenco-administered with ZEPATIER.(10 mg singledose)/ elbasvir(50 mg once daily)/grazoprevir(200 mg oncedaily)  ↑ Rosuvasta tin 
 AUC 2.26 (1.89, 2.69)Cmax 
5.49 (4.29, 7.04) C24 
0.98 (0.84, 1.13) (intestinal BCRP inhibition)
↔ Elbasvir 
 AUC 1.09 (0.98, 1.21)Cmax 
1.11 (0.99, 1.26) C24 0.96 (0.86, 1.08)
↔ Grazoprevir 
 AUC 1.01 (0.79, 1.28)Cmax 0.97 (0.63, 1.50)  C24 0.95 (0. 87, 1.04) Fluvastatin 
 Lovastatin 
 Simvastatin 
 Interaction not studied. Expected: 
↑ Fluvastatin(primarily due to intestinal BCRP inhibition)
↑ Lovastatin(CYP3 A inhibition) 
↑ Simvastatin(primarily due to intestinal BCRP inhibitionand CYP3A inhibit ion)The dose of  f luvastatin, lovastatin, orsimvastatin should not exceed a daily doseof  20  mg when co -administered with 
 ZEPATIER.Pitavastatin(1 mg single do se)/grazoprevir(200 mg oncedaily) ↔ Pitavastatin  AUC 1.11 (0.91, 1.34)Cmax 1.27 (1.07,  1.52) 
↔ Grazoprevir 
 AUC 0.81 (0.70, 0.95)Cmax 
0.72 (0.57, 0.92) C24 
0.91 (0.82, 1.01) No dose adjustment
 is required .16Medicin alproduct bytherapeuticareas Effects on medi cinal product levels. Mean ratio (90
 
% confidence
 interv al)for AUC, Cmax, C12 or C24(likely mechanism of interaction)Recom mendation concerning co
-administration with ZEPATIERPravastatin(40 mg singledose)/ elbasv ir(50 mg once daily)/grazoprevir(200 mg oncedaily) ↔ Pravastatin 
 AUC 1.3 3 (1.09, 1.64)Cmax 1.28 (1.05, 1.55)
↔ Elbasvir 
 AUC 0.98 (0.93, 1.02)Cmax 
0.97 (0.89, 1.05) C24 0.97 (0.92, 1.02)
↔ Grazoprevir 
 AUC 1.24 (1.00, 1.53)Cmax 
1.42 (1.00, 2.03) C24 
1.07 (0.99, 1.16) No dose adjustment is required
.IMMUNOSUPPRESSANTSCiclosporin  (400 mg single dose)/ elbasvir (50 mg once daily)/ grazoprevir (200 mg oncedaily) ↔ Elbasvir 
 AUC 1.98 (1.84, 2.13)Cmax 
1.95 (1.84, 2.07) C24 
2.21 (1.98, 2.47) 
↑ Grazoprevir 
 AUC 15.21 (12.83, 18.04)Cmax 
17.00 (12.94, 22.34) C24 3.39 (2.82 , 4.09) (due in part to OATP1B and CYP3Ainhibition)
↔ Ciclosporin 
 AUC 0.96 (0.90, 1.02)Cmax 
0.90 (0.85, 0.97) C12 
1.00 (0.92, 1.08) Co-administration is contraindicated.Mycophenolatemof etil(1,000  mg singledose)/ elbasvir(50 mg once daily)/grazoprevir(200 mg oncedaily) ↔ Elbasvir 
 AUC 1.07 (1.00, 1.14)Cmax 
1.07 (0.98, 1.16) C24 
1.05 (0.97, 1.14) 
↔ Grazoprevir 
 AUC 0.74 (0.60, 0.92)Cmax 
0.58 (0.42, 0.82) C24 0.97 (0.89, 1.06) 
↔ Mycophenolic acid 
 AUC 0.95 (0.87, 1.03)Cmax 0.85 (0.67, 1 .07) No dose adjustment is required
.17Medicin alproduct bytherapeuticareas Effects on medi cinal product levels. Mean ratio (90
 
% confidence
 interv al)for AUC, Cmax, C12 or C24(likely mechanism of interaction)Recom mendation concerning co
-administration with ZEPATIERPrednisone(40 mg singledose)/ elbasvir(50 mg once daily)/grazoprevir(200 mg once daily ↔ Elbasvir 
 AUC 1.17 (1.11, 1.24)Cmax 1.25 (1. 16, 1.35) C24 
1.04 (0.97, 1.12) 
↔ Grazoprevir 
 AUC 1.09 (0.95, 1.25)Cmax 1.34 (1.10, 1.62 ) C24 
0.93 (0.87, 1.00) 
↔ Prednisone 
 AUC 1.08 (1.00, 1.17)Cmax 
1.05 (1.00, 1.10) 
↔ Prednisolone 
 AUC 1.08 (1.01, 1.16)Cmax 
1.04 (0.99, 1.09) No dose adjustment is required .Tacrolimus(2 mg single dose)/elbasvir (50  mgonce daily)/grazoprevir(200 mg oncedaily) ↔ Elbasvir 
 AUC 0.97 (0.90, 1.06)Cmax 
0.99 (0.88, 1.10) C24 
0.92 (0.83, 1.02) 
↔ Grazoprevir 
 AUC 1.12 (0.97, 1.30)Cmax 
1.07 (0.83, 1.37) C24 0.94 (0.87, 1.02) 
↑ Tacrolimus 
 AUC 1.43 (1.24, 1.64)Cmax 
0.60 (0.52, 0.69) C12 1.70 (1.49 , 1.94) (CYP3A inhibition)Frequent monitoring of  tacrolimus wholeblood concentrations, changes in renalf unction, and tacrolimus
-associatedadverse events upon the initiation of  co
-administration is recommended.
 Closemonitoring and potential dose adju stmentof  tacrolimus may be required duringtherapy, as tacrolimus levels may decreaserelated to clearance of  HCV.KINASE INHIBITORSunitinib  Interaction not studied. Expected: 
↑ sunitinib(possibly due to intestinal BCRP inhibition)Co-administration of  ZEPATIER withsunitinib may increase sunitinibconcentrations leading to an increased riskof  sunitinib -associated adverse events.Use with caution; dose adjustment ofsunitinib  may be required.18Medicin al product by therapeutic areas  Effects on medi cinal product levels. Mean ratio (90
 
% confidence
 interv al)for AUC, Cmax, C12 or C24(likely mechanism of interaction)Recom mendation concerning co
-administration with ZEPATIEROPIOID -SUBSTITUTION THERAPYBuprenorphine/naloxone(8 mg/2  mg single dose)/ elbasvir (50 mg single dose)
 ↔ Elbasvir 
 AUC 1.22 (0.98, 1.52)Cmax 
1.13 (0.87, 1.46) C24 
1.22 (0.99, 1.51) 
↔ Buprenorphine 
 AUC 0.98 (0.89, 1.08)Cmax 0.94 ( 0.82, 1.08) C24 0.98 (0.88, 1.09)
↔ Naloxone 
 AUC 0.88 (0.76, 1.02)Cmax 0.85 (0.66, 1.09)No dose adjustment is required
.(8-24 mg/2 -6 mgonce daily)/grazoprevir(200 mg oncedaily)↔ Grazoprevir 
 AUC 0.80 (0.53, 1.22)Cmax 
0.76 (0.40, 1.44) C24 0.69 (0.54, 0.88) 
↔ Buprenorphine 
 AUC 0.98 (0.81, 1.19)Cmax 
0.90 (0.76, 1.07) Methadone(20-120 mg oncedaily)/ elbasvir(50 mg once daily) ↔ R -Methadone 
 AUC 1.03 (0.92, 1.15)Cmax 
1.07 (0.95, 1.20) C24 
1.10 (0.96, 1.26) 
↔ S-Methadone 
 AUC 1.09 (0.94,  1.26)Cmax 
1.09 (0.95, 1.25) C24 1.20 (0.98, 1.47)No dose adjustment is required
. (20-150 mg oncedaily)/ grazoprevir(200 mg oncedaily) ↔ R -Methadone 
 AUC 1.09 (1.02, 1.17)Cmax 
1.03 (0.96, 1.11) 
↔ S-Methadone 
 AUC 1.23 (1.12, 1.35)Cmax 1.15 (1. 07, 1.25)ORAL CONTRACEPTIVESEthinyl oestradiol (EE) / Levonorgestrel (LNG)(0.03  mg EE/ 
0.15 mg LNG single -dose)/ elbasvir (50  mg once daily)  
 ↔ EEAUC 1.01 (0.97, 1.05)Cmax 
1.10 (1.05, 1.16) 
↔ LNGAUC 1.14 (1.04, 1.24)Cmax 1.02 (0.95, 1.08)No dose adjustment is required
.(0.03  mg EE/ 
0.15 mg LNG single -dose)/ grazoprevir (200 mg once daily)  ↔ EEAUC 1.10 (1.05, 1.14)Cmax 
1.05 (0.98, 1.12) 
↔ LNGAUC 1.23 (1.15, 1.32)Cmax 0.93 (0.84, 1.03)19Medicin al product by therapeutic areas  Effects on medi cinal product levels. Mean ratio (90
 
% confidence
 interv al)for AUC, Cmax, C12 or C24(likely mechanism of interaction)Recom mendation concerning co
-administration with ZEPATIERPHOSPHATE BINDERSCalcium acetate
 (2,668  mg si ngle dose)/ elbasvir (50 mg single dose)/ grazoprevir (100 mg singledose) ↔ Elbasvir 
 AUC 0.92 (0.75, 1.14) Cmax 
0.86 (0.71, 1.04) C24 0.87 (0.70, 1.09)
↔ Grazoprevir 
 AUC 0.79 (0.68, 0.91)Cmax 
0.57 (0.40, 0.83) C24 0.77 (0.61, 0.99)No dose adjustment is required .Sevelamercarbonate(2,400  mg singledose)/ elbasvir(50 mg singledose)/ grazoprevir(100 mg singledose) ↔ Elbasvir 
 AUC 1.13 (0.94, 1.37) Cmax 
1.07 (0.88, 1.29) C24 1.22 (1.02, 1.45)
↔ Grazoprevir 
 AUC 0.82 (0.68, 0.99) Cmax 0.53 ( 0.37, 0.76) C24 0.84 (0.71, 0.99)SEDATIVESMidazolam(2 mg single dose)/grazoprevir(200 mg oncedaily)↔  Midazolam 
 AUC 1.34 (1.29, 1.39)Cmax 
1.15 (1.01, 1.31) No dose adjustment is required
. STIMULANTSModaf inil 
 Interaction not studied. Expe cted: 
↓ Elbasvir
↓ Grazoprevir(CYP3A or P -gp induction)Co-administration is contraindicated.Paediatric population 
 Interaction studies have only been perf ormed in adults.
